Literature DB >> 1357189

Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.

D H Gabuzda1, K Lawrence, E Langhoff, E Terwilliger, T Dorfman, W A Haseltine, J Sodroski.   

Abstract

The viral infectivity factor gene vif of human immunodeficiency virus type 1 has been shown to affect the infectivity but not the production of virus particles. In this study, the effect of vif in the context of the HXB2 virus on virus replication in several CD4+ T-cell lines was investigated. vif was found to be required for replication in the CD4+ T-cell lines CEM and H9 as well as in peripheral blood T lymphocytes. vif was not required for replication in the SupT1, C8166, and Jurkat T-cell lines. The infectivity of vif-defective viruses depended on the cell type in which the virus was produced. In CEM cells, vif was required for production of virus capable of initiating infection in all cell lines studied. vif-defective virus produced by SupT1, C8166, and Jurkat cells and the monkey cell line COS-1 could initiate infection in multiple cell lines, including CEM and H9. These results suggest that vif can compensate for cellular factors required for production of infectious virus particles that are present in some cell lines such as SupT1, C8166, and Jurkat but are absent in others such as CEM and H9 as well as peripheral blood T lymphocytes. The effect of vif was not altered by deletion of the carboxyl terminus of gp41, a proposed target for vif (B. Guy, M. Geist, K. Dott, D. Spehner, M.-P. Kieny, and J.-P. Lecocq, J. Virol. 65:1325-1331, 1991). These studies demonstrate that vif enhances viral infectivity during virus production and also suggest that vif is likely to be important for natural infections.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357189      PMCID: PMC240141     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells.

Authors:  D Dedera; W Hu; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

2.  Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication.

Authors:  P A Luciw; C Cheng-Mayer; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

3.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

4.  Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions.

Authors:  J Sodroski; W C Goh; C Rosen; A Tartar; D Portetelle; A Burny; W Haseltine
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

5.  A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses.

Authors:  T H Lee; J E Coligan; J S Allan; M F McLane; J E Groopman; M Essex
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

6.  The HIV 'A' (sor) gene product is essential for virus infectivity.

Authors:  K Strebel; D Daugherty; K Clouse; D Cohen; T Folks; M A Martin
Journal:  Nature       Date:  1987 Aug 20-26       Impact factor: 49.962

7.  Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera.

Authors:  N C Kan; G Franchini; F Wong-Staal; G C DuBois; W G Robey; J A Lautenberger; T S Papas
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

8.  Three novel genes of human T-lymphotropic virus type III: immune reactivity of their products with sera from acquired immune deficiency syndrome patients.

Authors:  S K Arya; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

9.  Construction and use of a replication-competent human immunodeficiency virus (HIV-1) that expresses the chloramphenicol acetyltransferase enzyme.

Authors:  E F Terwilliger; B Godin; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

10.  Nucleotide sequence and genomic organization of feline immunodeficiency virus.

Authors:  R L Talbott; E E Sparger; K M Lovelace; W M Fitch; N C Pedersen; P A Luciw; J H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

View more
  197 in total

1.  Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.

Authors:  R E Kiernan; A Ono; E O Freed
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 3.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

4.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

6.  HIV-1 Vif promotes the G₁- to S-phase cell-cycle transition.

Authors:  Jiangfang Wang; Emma L Reuschel; Jason M Shackelford; Lauren Jeang; Debra K Shivers; J Alan Diehl; Xiao-Fang Yu; Terri H Finkel
Journal:  Blood       Date:  2010-12-13       Impact factor: 22.113

7.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.

Authors:  Louis Alexander; Mary Janette Aquino-DeJesus; Michael Chan; Warren A Andiman
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

9.  Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.

Authors:  J Goncalves; B Shi; X Yang; D Gabuzda
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.

Authors:  C Aiken; D Trono
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.